Naloxone

Evidence Level: N/A

Predicted Indications: 0

Naloxone

Pharmacist Assessment Report

Naloxone: Known uses and market status in Australia

Summary

The TxGNN model has no candidate with a score of 0.99 or higher for Naloxone, so there is currently no new predicted indication. The drug’s recorded uses are listed below.

Quick overview

Item	Content
New predicted indications	None (no model candidate scored 0.99 or higher)
Known uses recorded for this drug	3
Evidence level	Not applicable
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)

Known uses recorded for this drug

Approved (supported by a licence or label)

Indication	Source
opioid-related disorders	licence in another country

Indication	Approved category
none	none

Relations recorded in the knowledge graph (no approval found)

Indication
morphine dependence
opiate dependence

Australia Market Information

Licence	Product	Dosage form	Status
10783M	Naloxone Hydrochloride (DBL)	Injection containing naloxone hydrochlor	Valid

Safety Considerations

Contraindication-related disease associations (knowledge graph, not label text): The knowledge graph links naloxone with caution or contraindication in the following groups, which should be verified against the Product Information:

Cardiovascular: long QT syndrome, torsades de pointes, sudden cardiac arrest, heart conduction disease, orthostatic hypotension, hypotensive disorder, postural orthostatic tachycardia syndrome, multiple system atrophy
Neurological/respiratory: epilepsy, chronic obstructive pulmonary disease, respiratory failure
Hepatic/renal: liver disease, kidney disease, chronic hepatitis B and C infection, gallbladder disease
Endocrine: adrenal insufficiency, Addison disease, hypothyroidism, myxoedema
Other: inflammatory bowel disease, benign prostatic hyperplasia

Drug Interactions: 88 interactions were identified. The main ones are:

Major: droperidol
Moderate: opioid agonists, including fentanyl, morphine, codeine, tramadol, oxycodone, methadone, hydrocodone, alfentanil, remifentanil and sufentanil; and opioid-related agents such as methylnaltrexone, naldemedine, naloxegol, butorphanol and binimetinib
Minor: hydrocortisone

Naloxone can precipitate withdrawal in opioid-dependent patients. Preclinical data also report naloxone-induced seizures in the context of encephalitis. Please refer to the TGA-approved Product Information (PI) for full warnings and contraindications.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.